Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets
Authors
Keywords
Lymphocytes, Multiple sclerosis, NK cells, Regulatory T cells, Cytotoxic T cells, T cells, Memory T cells, Blood
Journal
PLoS One
Volume 15, Issue 2, Pages e0228380
Publisher
Public Library of Science (PLoS)
Online
2020-02-04
DOI
10.1371/journal.pone.0228380
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulatory T cells in multiple sclerosis and myasthenia gravis
- (2017) K. M. Danikowski et al. Journal of Neuroinflammation
- Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
- (2017) Tatiana Plavina et al. NEUROLOGY
- The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
- (2017) Guillermo Izquierdo et al. PLoS One
- Neurons and T cells: Understanding this interaction for inflammatory neurological diseases
- (2015) Lidia Yshii et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis
- (2015) Jürgen Haas et al. Multiple Sclerosis Journal
- Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis
- (2015) Jürgen Haas et al. Multiple Sclerosis Journal
- Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
- (2015) Zi-Ye Song et al. PLoS One
- B cells in Multiple Sclerosis: Good or bad guys?
- (2014) Franziska Hoffmann et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
- (2014) R. J. Fox et al. NEUROLOGY
- The who's who of T-cell differentiation: Human memory T-cell subsets
- (2013) Yolanda D. Mahnke et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis
- (2013) D. Henault et al. NEUROLOGY
- Increased B Cell and Cytotoxic NK Cell Proportions and Increased T Cell Responsiveness in Blood of Natalizumab-Treated Multiple Sclerosis Patients
- (2013) Johan Mellergård et al. PLoS One
- Natural killer cell distribution and trafficking in human tissues
- (2012) Paolo Carrega et al. Frontiers in Immunology
- Impact of sphingosine 1-phosphate modulation on immune outcomes
- (2011) D. D. Pinschewer et al. NEUROLOGY
- The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators
- (2011) B. Soliven et al. NEUROLOGY
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
- (2009) Makoto Miyara et al. IMMUNITY
- T-bet–dependent S1P5expression in NK cells promotes egress from lymph nodes and bone marrow
- (2009) Craig N. Jenne et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid
- (2009) J. Mellergård et al. Multiple Sclerosis Journal
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
- (2008) M. Mehling et al. NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now